BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etribnabdione readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etribnabdione\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06774040-7938@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Etribnabdione: Phase 2 readout est. (NCT06774040)
DESCRIPTION:Etribnabdione\, phase 2\, Atherosclerotic Cardiovascular Diseas
 e.\nStudy: Evaluation of Safety\, Tolerability and Preliminary Efficacy of
  Etrinabdione in Patients With Peripheral Arterial Disease\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/etribnabdione#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06774040
URL:https://assetmemo.bio/drug/etribnabdione#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
